In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.
The comparative in vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone, was evaluated against 511 clinical isolates. MICs of trovafloxacin were fourfold higher than those of ciprofloxacin for 184 Enterobacteriaceae and 110 non-fermentative gram-negative bacilli. However, trovafloxacin was 16-fold more active than ciprofloxacin against 162 gram-positive staphylococci, pneumococci, streptococci, and enterococci, and two- to fourfold more active against Haemophilus influenzae and Moraxella catarrhalis. MICs of trovafloxacin were correspondingly higher for strains with acquired resistance to ciprofloxacin.
Verbist
L
L
Department of Microbiology, University Hospital St. Rafaël, Leuven, Belgium.
Verhaegen
J
J
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000494:pharmacology*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D002939:Ciprofloxacin; C080163:trovafloxacin